

# Accepted Manuscript

Title: A liquid chromatography–tandem mass spectrometry-based investigation of the lamellar interstitial metabolome in healthy horses and during experimental laminitis induction

Author: C.E. Medina-Torres, A.W. van Eps, L.K. Nielsen, M.P. Hodson

PII: S1090-0233(15)00322-6

DOI: <http://dx.doi.org/doi: 10.1016/j.tvjl.2015.07.031>

Reference: YTVJL 4580

To appear in: *The Veterinary Journal*

Accepted date: 31-7-2015



Please cite this article as: C.E. Medina-Torres, A.W. van Eps, L.K. Nielsen, M.P. Hodson, A liquid chromatography–tandem mass spectrometry-based investigation of the lamellar interstitial metabolome in healthy horses and during experimental laminitis induction, *The Veterinary Journal* (2015), <http://dx.doi.org/doi: 10.1016/j.tvjl.2015.07.031>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **A liquid chromatography–tandem mass spectrometry-based investigation of the**  
2 **lamellar interstitial metabolome in healthy horses and during experimental laminitis**  
3 **induction**

4  
5 C.E. Medina-Torres <sup>a,1,\*</sup>, A.W. van Eps <sup>a</sup>, L.K. Nielsen <sup>b</sup>, M.P. Hodson <sup>b,c,d</sup>

6  
7  
8 <sup>a</sup> *Australian Equine Laminitis Research Unit, School of Veterinary Science, Faculty of*  
9 *Science, The University of Queensland, Gatton Campus, Gatton, QLD, 4343, Australia.*

10 <sup>b</sup> *Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of*  
11 *Queensland, Brisbane St Lucia, QLD, 4072, Australia.*

12 <sup>c</sup> *Metabolomics Australia – Queensland Node, AIBN, The University of Queensland,*  
13 *Brisbane St Lucia, QLD, 4072, Australia.*

14 <sup>d</sup> *School of Pharmacy, The University of Queensland, Woolloongabba, QLD 4102, Australia*

15  
16  
17 \* Corresponding author. Tel.: +49 89 2180 2627

18 E-mail address: [c.medina@pferd.vetmed.uni-muenchen.de](mailto:c.medina@pferd.vetmed.uni-muenchen.de) (C.E. Medina-Torres)

19  
20  
21  
22 <sup>1</sup> Present address: Equine Medicine and Reproduction, The Equine Hospital, Faculty of  
23 Veterinary Medicine, Ludwig-Maximilians University of Munich, Veterinaerstrasse 13,  
24 80539 Munich, Germany.  
25  
26  
27  
28  
29

## 30 **Highlights for Review**

- 31 • Metabolomic analysis of lamellar dialysate can differentiate horses developing experimental  
32 sepsis-associated laminitis from controls.
- 33 • Malate, pyruvate, aconitate and glycolate in lamellar dialysate, and malate alone in plasma,  
34 were identified as the source of differentiation.
- 35 • Changes in energy metabolism intermediates in the lamellar interstitium occurred during  
36 laminitis development and were not present in plasma.
- 37 • Further investigation of local bioenergetic failure as a cause of laminitis due to sepsis is  
38 warranted.
- 39 • Open profiling could further assess changes to the metabolome elicited by laminitis.

## 40 **Abstract**

41 Lamellar bioenergetic failure is thought to contribute to laminitis pathogenesis but  
42 current knowledge of lamellar bioenergetic physiology is limited. Metabolomic analysis (MA)  
43 can systematically profile multiple metabolites. Applied to lamellar microdialysis samples  
44 (dialysate), lamellar bioenergetic changes during laminitis (the laminitis metabolome) can be  
45 characterised. The objectives of this study were to develop a technique for targeted MA of  
46 lamellar and skin dialysate in normal horses, and to compare the lamellar and plasma  
47 metabolomic profiles of normal horses with those from horses developing experimentally  
48 induced laminitis. Archived lamellar and skin dialysate ( $n=7$ ) and tissue ( $n=6$ ) from normal  
49 horses, and lamellar dialysate and plasma from horses given either 10 g/kg oligofructose  
50 (treatment group, OFT;  $n=4$ ) or sham (control group, CON;  $n=4$ ) were analysed. The  
51 concentrations of 44 intermediates of central carbon metabolism (CCM) were determined  
52 using liquid chromatography – tandem mass spectrometry. Data were analysed using  
53 multivariate (MVA) and univariate (UVA) analysis methods.

54

55 The plasma metabolome appeared to be more variable than the lamellar metabolome  
56 by MVA, driven by malate, pyruvate, aconitate and glycolate. In lamellar dialysate, these  
57 metabolites decreased in OFT horses at the later time points. Plasma malate was markedly  
58 increased after 6 h in OFT horses. Plasma malate concentrations between OFT and CON at  
59 this time point were significantly different by UVA. MA of lamellar CCM was capable of

2

60 differentiating horses developing experimental laminitis from controls. Lamellar malate,  
61 pyruvate, aconitate and glycolate, and plasma malate alone were identified as the source of  
62 differentiation between OFT and CON groups. These results highlighted clear discriminators  
63 between OFT and CON horses, suggesting that changes in energy metabolism occur locally in  
64 the lamellar tissue during laminitis development. The biological significance of these  
65 alterations requires further investigation.

66

67 *Keywords:* Bioenergetic; Chromatography; Energy metabolism; Metabolomic; Sepsis.

Accepted Manuscript

## 68 **Introduction**

69 Failure of lamellar energy metabolism (bioenergetic failure) is thought to be involved in  
70 the pathophysiology of sepsis-related (Belknap et al., 2009), endocrinopathic (French and  
71 Pollitt, 2004; Pass et al., 1998) and supporting limb (van Eps et al., 2010) laminitis in the  
72 horse. High lamellar glucose consumption has been demonstrated both in vitro (Pass et al.,  
73 1998) and in vivo (Wattle and Pollitt, 2004). Lamellar hemidesmosomes, specialised  
74 multiprotein complexes that participate in the attachment of epithelial cells to their underlying  
75 basement membrane (Borradori and Sunnenberg, 1999), are lost in the absence of glucose and  
76 the dermo-epidermal attachment becomes weak (French and Pollitt, 2004; Pass et al., 1998). It  
77 has recently been proposed that sepsis-related laminitis may also occur secondary to  
78 inappropriate utilisation of energy substrates (i.e. glucose) (Belknap et al., 2009), as is thought  
79 to occur in sepsis-related organ dysfunction in humans (Callahan and Supinski, 2005;  
80 Fullerton and Singer, 2011; Leverve, 2007; Singer, 2008). Despite the purported role of  
81 energy failure in laminitis pathogenesis, current knowledge about lamellar bioenergetic  
82 physiology is limited.

83

84 The goal of metabolomic analysis (MA) is the comprehensive measurement of  
85 metabolite concentrations associated with a biological system at the cellular, tissue or whole  
86 organism level (Goodacre et al., 2004). MA results in the systematic profiling of multiple  
87 metabolites and their temporal (or population) changes in biofluids and tissues (Oliver et al.,  
88 1998). It can be undertaken using two broadly different approaches, namely, open (or  
89 untargeted) profiling metabolomics or targeted (quantitative) metabolomics (Goodacre et al.,  
90 2004). Targeted metabolomics in veterinary science can be regarded as an extension of a  
91 clinical chemistry panel whereby several predetermined analytes are quantitatively measured  
92 to assess their role in an underlying process. A recent open metabolomics study of serum from  
93 horses before and after experimentally-induced laminitis revealed evidence of dysregulation

94 of fatty acid metabolism, accumulation of organic acids (lactate) and identified that the amino  
95 acid citrulline decreased in serum prior to the onset of clinical laminitis (foot pain) (Steelman  
96 et al., 2014).

97  
98 Using tissue microdialysis, our laboratory has examined the major energy metabolites  
99 (glucose, lactate and pyruvate) in the interstitium of the lamellar and skin dermis in normal  
100 horses over 24 h (Medina-Torres et al., 2014). In the current study we sought to combine  
101 tissue microdialysis and metabolomics to examine the changes in lamellar energy central  
102 carbon metabolism that occur locally during the development of laminitis. The analysis of the  
103 three major energy metabolites previously described (Medina-Torres et al., 2014) was  
104 considerably extended in this study by measuring the major energy metabolite pathway  
105 intermediates of glycolysis, the pentose phosphate pathway and the Krebs cycle, as well as  
106 nucleotides and co-factors. The primary aim of this MA was to determine the source and/or  
107 metabolic sequelae of any perturbation caused by experimental induction of laminitis and  
108 subsequent bioenergetic failure. Our objectives were: (1) to develop a reliable and  
109 reproducible technique for MA of equine lamellar and skin microdialysis samples (dialysates)  
110 and tissue samples using high performance liquid chromatography (HPLC) coupled to tandem  
111 mass spectrometry (MS/MS); (2) to compare dialysate and tissue extracts of lamellar tissue  
112 with the skin using targeted (quantitative) MA, and (3) to use targeted metabolomics to  
113 compare serial lamellar and plasma samples from normal horses with those of horses  
114 undergoing laminitis induction using the oligofructose (OF) model.

115

## 116 **Materials and methods**

### 117 *Samples*

118 Archived (< 1 year at -80 °C) samples from adult Standardbred horses were used for  
119 analysis. Samples were collected during previous studies approved by The University of

120 Queensland Animal Ethics Committee (AEC) that monitors compliance with the Animal  
121 Welfare Act (2001) and the Code of Practice for the care and use of animals for scientific  
122 purposes (current edition) (approval numbers SVS/257/11/GJRF of 6 October 2011 and  
123 SVS/338/11/UQ of 13 January 2012).

124

125 Lamellar and skin microdialysis samples were obtained every 2 h over a 24 h study  
126 period from seven healthy horses; skin and lamellar tissue blocks were harvested from six  
127 healthy horses immediately after euthanasia, and lamellar microdialysis and plasma samples  
128 were obtained from eight horses at 0, 6, 12 and 24 h after nasogastric administration of either  
129 a bolus dose of 10 g/kg OF (Invita) (treatment group, OFT;  $n=4$ ) as previously described (van  
130 Eps and Pollitt, 2006), or sham treatment (control group, CON;  $n=4$ ).

131

132 The OFT horses had developed Obel grade 1 lameness (Obel, 1948) at 18 - 22 h after  
133 OF dosing and had histological evidence of acute laminitis at 48 h. Dialysate was collected  
134 with coaxial microdialysis probes with a  $0.5 \times 10$  mm, 100 kDa cut-off membrane (CMA20,  
135 CMA-Microdialysis), inserted into the lamellar tissue of one forelimb and into the skin dermis  
136 at the tail base as previously described (Medina-Torres et al., 2014). All probes were perfused  
137 with isotonic, polyionic sterile perfusion fluid (T1, CMA-Microdialysis) containing 40 g/L  
138 dextran-70 (Sigma-Aldrich) to prevent perfusate loss (Rosdahl et al., 1997). Plasma was  
139 separated by immediate centrifugation ( $15,000 \times g$ , 10 min) of whole blood samples collected  
140 into heparinised tubes (Vacuette, Greiner Bio-One) in OFT and CON horses via a 16G  
141 indwelling catheter (Mila International) placed aseptically in the right jugular vein.

142

#### 143 *Development and optimization of LC-MS/MS*

144 In each sample, central carbon metabolism (CCM) was assessed by liquid  
145 chromatography - tandem mass spectrometry (LC-MS/MS) using a targeted method. For

146 lamellar and skin microdialysis samples, assessment of the perfusion fluid (perfusate) was  
147 performed to determine its suitability as a calibration matrix. The performance of a perfusate-  
148 based calibration was then measured and compared against an aqueous 'blank' calibration  
149 through standard addition of the metabolite panel (reference standards; Sigma-Aldrich) to the  
150 perfusate matrix. Thereafter lamellar and skin microdialysis samples were measured to assess  
151 the need for further optimization based upon sample-related effects on the analytical system.

152

153 To analyse the metabolite composition of lamellar and skin dermis tissue sections,  
154 metabolites were extracted using a procedure adapted from Want et al. (2013). In brief, 50 mg  
155 of each sample were sliced with a scalpel, suspended in 2 mL of 1:1 methanol:purified water  
156 plus 2  $\mu\text{L}$  1 mM azidothymidine (AZT) as an internal quantitative standard, and homogenised  
157 for 5 min at 20,000 rpm using an Omni TH Homogenizer (Omni International). Purified water  
158 was generated using a water purification unit (Elga Purelab Classic; Veolia Water Solutions  
159 and Technologies). The fluid fraction/supernatant was collected and centrifuged for 15 min at  
160 13,000  $g$  at 4  $^{\circ}\text{C}$ . The supernatant (800  $\mu\text{L}$ ) was retrieved and chloroform (800  $\mu\text{L}$ ) added  
161 before vortexing for 15 s. Samples were then centrifuged for 10 min at 13,000  $g$  at 4  $^{\circ}\text{C}$  and  
162 the supernatant (upper polar phase; 600  $\mu\text{L}$ ) collected. Addition of chloroform (600  $\mu\text{L}$ ),  
163 vortexing and centrifugation were repeated. The upper polar phase was collected and dried  
164 down in a vacuum centrifuge (Eppendorf Concentrator Plus) for 180 min at 45  $^{\circ}\text{C}$  using the  
165 V-AQ program. The dried sample was resuspended immediately in 100  $\mu\text{L}$  of purified water  
166 for LC/MS-MS analysis. Plasma (50  $\mu\text{L}$ ) was processed using the same extraction procedures,  
167 without the need for the initial tissue homogenization step.

168

169 LC-MS/MS data were acquired using a Dionex UltiMate 3000 LC system coupled to an  
170 ABSciex 4000 QTRAP mass spectrometer as described by Dietmair et al. (2012), with the  
171 following modifications: the analytical column was equipped with a pre-column Security



172 Guard Gemini-NX C18 4 × 2 mm I.D. cartridge (Phenomenex) and five additional analytes  
173 were quantified, as well as AZT (internal standard). The LC system was controlled by  
174 Chromeleon software v6.80<sup>n</sup>, and chromatographic separation achieved by injecting 10 µL  
175 onto a Gemini-NX C18 150 × 2 mm I.D., 3 µm 110 Å particle column (Phenomenex). The  
176 column oven temperature was controlled and maintained at 55 °C throughout the acquisition  
177 and the mobile phases (adapted from Luo et al., 2007), were as follows: 7.5 mM aqueous  
178 tributylamine (puriss plus grade; Sigma-Aldrich) adjusted to pH 4.95 (±0.05) with glacial AR-  
179 grade acetic acid (eluent A; Labscan) and LC-grade acetonitrile (eluent B; Labscan). The  
180 mobile phase flow rate was maintained at 300 µL/min throughout the gradient profile (Table  
181 1), and introduced directly into the MS with no split.

182

183 The MS was equipped with a TurboV electrospray source operated in negative  
184 ionisation mode, and data acquisition controlled by Analyst v1.5.2 software (ABSciex). The  
185 following optimised parameters were used to acquire scheduled Multiple Reaction Monitoring  
186 (sMRM) data: ion spray voltage -4500V, nebulizer (GS1), auxiliary (GS2), curtain (CUR)  
187 and collision (CAD) gases were 60, 60, 20 and medium (arbitrary units), respectively,  
188 generated in a N300DR nitrogen generator (Peak Scientific). The auxiliary gas temperature  
189 was maintained at 350 °C.

190

191 A total of 44 analytes were quantified using HPLC-MS/MS; the analytes and analyte-  
192 dependent parameters for the detection of central carbon metabolites are presented in  
193 Supplementary Table 1. For all analytes the entrance potential (EP) was -10 volts. Samples  
194 were run with sample- and analyte-relevant calibration standards and pooled quality control  
195 samples (Hodson et al., 2009; Sangster et al., 2006) to control for reproducibility of data  
196 acquisition and to ensure data integrity. The order of acquisition of the samples was  
197 randomised to remove/minimise any bias or batch effects related to sample type or, if

8

198 applicable, treatment regimes. Analyte stock solutions were prepared in purified water, and  
199 aliquots of each solution were mixed to achieve a final calibrant solution at 200  $\mu\text{M}$ . This  
200 calibrant solution was diluted to provide a total of 20 calibration standards at 200, 150, 100,  
201 90, 70, 50, 40, 25, 12.5 and 1:1 serial dilutions to 0.006  $\mu\text{M}$ , constituting  $7 \leq x \leq 20$   
202 calibration points for all analytes to account for differential responses in the mass  
203 spectrometer.

204

#### 205 *Data processing and statistical analysis*

206 Data acquired by HPLC-MS/MS were processed using MultiQuant v2.1.1 software  
207 (ABSciex). Multivariate analysis (MVA) of the data was performed using SIMCA v13.0.3.0  
208 software (MKS Umetrics). Two MVA methods were applied, namely principal component  
209 analysis (PCA) and orthogonal projection to latent structures-discriminant analysis (OPLS-  
210 DA). For more information relating to these methods see Trygg et al. (2007) and Bylesjö et al.  
211 (2006).

212

213 In normal horses, results were compared between lamellar and skin dermis dialysate,  
214 and between lamellar dialysate samples and tissue sections. In the OF study animals, results  
215 were compared between lamellar dialysate from OFT and CON groups, between time points  
216 within each sample group, and between lamellar dialysate and plasma. Using GraphPad Prism  
217 v6.00 for Windows, univariate analysis (UVA) was then performed on selected metabolites  
218 identified by MVA. The data were tested for normality using D'Agostino-Pearson omnibus  
219 K2 normality tests; non-parametric tests were applied if the data failed this test. Metabolite  
220 concentrations in lamellar dialysate and plasma were compared at each time point between  
221 OFT vs. CON horses. Significance was set at  $P < 0.05$ .

222

#### 223 **Results**

224 There was no evidence to suggest that, in comparison to a water-based calibration, the  
225 T1 solution with 40 g/L dextran-70 matrix caused any overt suppression or enhancement of  
226 the MS detection of analytes from CCM. Lamellar and skin microdialysis samples were  
227 subsequently measured successfully after extraction, so no further processing of the samples  
228 was required. The metabolite composition of both lamellar and skin tissue sections was also  
229 successfully determined; without extensive testing of multiple methods the extraction protocol  
230 was deemed suitable for characterisation of intracellular CCM analytes in these two tissues.

231

### 232 *Skin vs. lamellar dialysate*

233 Multivariate analysis was used to compare the data obtained from lamellar and skin  
234 dialysate, initially using PCA to summarise the major sources of variance in the data. Fig. 1a  
235 shows the PCA scores plot for this comparison and it is clear from this plot that the  
236 distributions of the samples from the skin and the lamellae were similar and approximately  
237 overlap each other. When applying alternative colouring to the PCA (Fig. 1b) based upon  
238 horse (subject), some structure to the variance can be observed relating to the horse from  
239 which the samples were taken. Supervision of the MVA using OPLS-DA was also unable to  
240 clearly separate skin and lamellar samples based upon their detectable metabolome in this  
241 experiment (Fig. 1c).

242

### 243 *Lamellar dialysate vs. plasma*

244 PCA of the metabolome of these samples showed clear differences, as observed in Fig.  
245 2a. In general the plasma metabolome appeared more variable than that of the dialysate. This  
246 was driven by central carbon metabolites such as malate, where clear differences were not  
247 only observed between plasma and lamellar dialysate but also between the control and treated  
248 groups. Marked increases in malate were seen, particularly at the 6 h time point in the  
249 plasma of OFT-treated subjects (Fig. 2c). Fig. 2b shows the loadings relating to the scores

250 plot in Fig. 2a and highlights the variables and therefore the metabolites that are influential in  
251 the differentiation between plasma and lamellar dialysate. Clearly observable group- and  
252 time-dependent metabolite profile differences were also noted for metabolic intermediates  
253 such as aconitate (Fig. 2d), pyruvate (Fig. 2e) and glycolate (Fig. 2f).

254

255 UVA of the lamellar dialysate revealed significantly ( $P<0.05$ ) higher malate at the 6 h  
256 time point and lower malate and aconitate at the 24 h time point in OFT horses compared with  
257 CON (Appendix: Supplementary Fig. 1). Pyruvate and glycolate concentrations were not  
258 found to be significantly different between OFT and CON, however a decrease in the  
259 concentrations of all four metabolites was apparent in the OFT group at the later time points,  
260 while concentrations remained stable in the CON group (Appendix: Supplementary Fig. 1).  
261 Plasma malate concentrations increased significantly at the 6 h time point in OFT compared  
262 to CON horses (Appendix: Supplementary Fig. 2).

263

#### 264 *OFT vs. CON*

265 After investigating the overall differences between metabolite concentrations in lamellar  
266 and plasma samples, a more directed analysis was performed to look specifically at the  
267 comparison between lamellar microdialysate samples from CON and OFT subjects, as well as  
268 comparing the same for plasma extracts. In the case of plasma extract samples, PCA and  
269 OPLS-DA models highlighted malate as the only major difference between the metabolome  
270 of the CON and OFT horses in plasma. In the case of the lamellar dialysate, models were  
271 generated for all time points other than the zero time point (i.e. before treatment) and  
272 therefore metabolomic differences were observed based upon OF treatment (Figs. 3 a-f).

273

#### 274 *Lamellar tissue extracts vs. skin tissue extracts*

275 A comparison of tissue extracts from lamellae and skin was also performed in an  
276 attempt to assess the central carbon metabolomic differences between these tissues. Figs. 4a-f  
277 show the supervised (OPLS-DA) separation of the two tissue extracts and highlights a number  
278 of clear differences in the central carbon metabolite content of these tissues. It should be  
279 noted that the extraction procedure was controlled with a generalised internal standard (AZT)  
280 to account for losses/reduced recovery, and that the differences observed are not due to a  
281 consistent increase of metabolites in one tissue after extraction, since metabolite levels are  
282 both higher and lower in one tissue compared to the other. The lamellar extracts were found to  
283 be more variable in metabolite content than the skin extracts, as can be observed by the tighter  
284 distribution of the skin samples in the scores plot (Fig. 4a).

285

#### 286 *Lamellar tissue extracts vs. lamellar dialysate*

287 The central carbon metabolome of lamellar tissue extracts was compared with that of  
288 the lamellar dialysate to ascertain how well the microdialysate metabolite profile reflects the  
289 lamellar tissue. Figs. 5a and b show the loadings from unsupervised (PCA) and supervised  
290 (OPLS-DA) analyses of the samples ( $n=6$ /group), with a separation in Fig. 5a clearly resolved  
291 by supervision in Fig. 5b. Column plots of four metabolites are shown in Figs. 5c-f to  
292 highlight the differences in profile for many of the metabolites, the vast majority of which  
293 have much greater concentration in lamellar tissue with the exception of malate (Fig. 5f),  
294 succinate and glucose 1-phosphate. A summary of the concentrations of all analytes for the  
295 various biofluid and tissue extracts are detailed in the Appendix at Supplementary Table 2.

296

#### 297 **Discussion**

298 A method for MA of equine lamellar and skin dialysate and tissue extracts was  
299 successfully developed and enabled measurement of the CCM in microdialysate, plasma and  
300 tissue extract samples.

301

302 Principal component analysis of the data from the lamellar and skin tissue of healthy  
303 adult horses demonstrated that, by comparison, lamellar and skin dialysate had a similar  
304 metabolite composition (Fig. 1a). When the PCA was coloured by subject (Fig. 1b) a pattern  
305 of variance related to the sample source (i.e. the horse) was observed. In general this means  
306 that the site of sampling (skin vs. lamellae) was not a major discriminating factor when  
307 considering possible differences in metabolome, whereas inter-subject variability showed a  
308 degree of influence on the metabolomic content of the tissues. Furthermore, OPLS-DA  
309 supervision of the MVA also failed to separate lamellar and skin dialysate samples based  
310 upon their CCM (Fig. 1c), meaning there was a degree of similarity in the metabolomic  
311 content of microdialysis samples obtained from these two collection sites. As the dialysate  
312 from both sites can be expected to contain metabolites that diffuse freely across the  
313 membrane, the similarities in dialysate composition demonstrates that in the normal (healthy)  
314 horse the interstitial fluid composition of the lamellar tissue is similar to that of the skin.

315

316 Clear differences between the metabolome of lamellar dialysate and plasma from CON  
317 and OFT subjects were observed with PCA (Fig. 2a). Unexpectedly, the metabolome of the  
318 plasma samples was found to be more variable than that of the lamellar dialysate. This finding  
319 may seem surprising given the homeostatic control of plasma metabolite concentrations in  
320 particular but could possibly be explained by two factors; firstly the plasma sample is a  
321 snapshot in time whereas the microdialysate sample is collected over a longer period and as  
322 such provides a more ‘averaged signal’ of metabolite concentrations; secondly, and linked to  
323 the first, the plasma sample is more likely to be affected by external influences such as  
324 feeding immediately prior to sample collection.

325

326 The variability in plasma was driven by four central carbon metabolites (i.e. malate,  
327 aconitate, pyruvate and glycolate; Figs. 2b-f), which were not only influential in the  
328 differentiation between the two tissue sample types, but also provided differentiation between  
329 the CON and OFT groups (e.g. significant increase in malate at the 6 h time point in OFT  
330 plasma). However, when looking specifically at the comparison between plasma extracts from  
331 CON and OFT subjects in isolation, only malate was indicated as a discriminatory metabolite.  
332 The time-related profile for malate suggests that the determination of plasma concentrations  
333 for this metabolite may be a suitable early predictor of laminitis development (at least in  
334 laminitis due to alimentary oligofructose overload), although further investigations with larger  
335 subject numbers would be required to confirm its utility. Furthermore, determination of  
336 plasma malate concentrations at intermediate time points (e.g. hourly sampling from 0 – 12 h  
337 after OF administration) would be necessary to identify the evolution of this rise in malate,  
338 the time point when the maximum concentration (peak) is reached, and its duration (i.e. the  
339 potential diagnostic window). However, as malate is an intermediate metabolite with  
340 important roles in energy producing pathways such as the tricarboxylic acid cycle (TCA) in  
341 animals (Alberts et al., 2008) as well as the glyoxylate cycle in bacteria (Kornberg and Krebs,  
342 1957), and the naturally occurring malate molecule (i.e. L-malate) is identical in bacteria and  
343 mammals (Alberts et al., 2008), the source of plasma malate in the present study cannot be  
344 determined. It could be a by-product of bacterial fermentation of OF in the gastrointestinal  
345 tract, which would be consistent with the timing of the increase in plasma in this experiment.  
346 If this is the case, the use of malate as a predictor of laminitis in naturally occurring laminitis  
347 might be precluded.

348

349 Contrary to malate, two different isoforms of lactate occur naturally: L-lactate in  
350 mammals and D-lactate in bacteria (Alberts et al., 2008). Thus, determining the plasma D-  
351 lactate concentration could help establish if this and other intermediate metabolites (such as

352 malate) originated in the intestinal lumen as a result of the bacterial disbiosis known to occur  
353 after OF administration (Millinovich et al., 2006). However, the LC-MS/MS method used in  
354 this study could not distinguish between the two lactate isoforms, and other means of  
355 differentiation were not attempted. Furthermore, plasma lactate was not a discriminatory  
356 metabolite between the CON and OFT groups. Though the absence of a discriminatory shift  
357 in plasma lactate concentrations might indicate that the source of other measured metabolites  
358 (including malate) may be other than the intestinal intraluminal bacteria, this cannot be  
359 established with our findings in the present study.

360

361 Thus, whether the discrimination between the CON and OFT groups observed with  
362 malate is attributable to an influx of bacterial metabolites from the intestine or a consequence  
363 of metabolic disruption attributable to the development of sepsis-associated laminitis in the  
364 horse remains to be determined. This could be an important future step in understanding the  
365 pathophysiology of sepsis-associated laminitis and in the identification of potential  
366 biomarkers for early disease diagnosis.

367

368 MA of lamellar dialysate was capable of differentiating between OFT and CON groups.  
369 The analysis highlighted two metabolites (malate and aconitate) as clear discriminators  
370 between OFT and CON horses. These results suggest that changes in energy metabolism do  
371 occur locally in the lamellar tissue during laminitis development and warrant further  
372 investigation using the lamellar microdialysis technique. However, the changes may not be  
373 biologically significant as they occurred in the later time points, coinciding with the onset of  
374 lameness (18–22 h), and after the developmental phase of the disease. This is further  
375 confounded by the fact that microdialysis is an interstitial sample, where the observed  
376 changes may not represent the true intracellular metabolic status and could be affected by  
377 other processes such as inflammation.



378

379 In general, lamellar tissue was found to have higher metabolite concentrations in  
380 comparison to lamellar dialysate, with the exception of malate, succinate and glucose 1-  
381 phosphate. The extracellular origin of the dialysate dictates that concentrations are likely to be  
382 lower than the intracellular pools, as the content of the dialysate consists for the most part of  
383 TCA intermediates and pyruvate, all of which are produced in the cellular cytoplasm.  
384 Assessing a more comprehensive dialysate metabolome using a larger microdialysis probe  
385 pore size and with the inclusion of amino acids, fatty acids and carbohydrates would be  
386 recommended for future studies in order to comprehensively examine lamellar metabolism  
387 during laminitis development. A similar approach was utilised recently for trapezius myalgia  
388 in humans (Hadrevi et al., 2013). Furthermore, concurrent assessment of regulatory enzymes  
389 of energy metabolism (glycolytic and oxidative) could help determine if lamellar energy  
390 failure is a feature of laminitis in the horse. Phosphofructokinase, a rate limiting enzyme of  
391 the glycolytic pathway, as well as electron transport chain components were genetically  
392 downregulated in muscle from a rodent sepsis model (Callahan and Supinski, 2005).

393

394 The main limitations of our study were the low number of subjects included and that  
395 only 4/13 time points collected were assessed in OFT and CON horses (due to financial and  
396 logistical restrictions). However, despite these limitations, targeted MA and MVA were  
397 successful in differentiating OFT and CON horses and potential plasma/lamellar dialysate  
398 biomarkers were identified.

399

## 400 **Conclusions**

401 MA of the lamellar dialysate samples for central carbon metabolites was found to be  
402 capable of differentiating horses developing experimental sepsis-associated laminitis from  
403 controls in the OF model. Malate, pyruvate, aconitate and glycolate in lamellar dialysate, and

16

404 malate alone in plasma, were identified as the source of differentiation between OFT and  
405 CON groups. The origin and clinical usefulness of these potential biomarkers for early  
406 identification of naturally occurring laminitis remain to be determined. These significant  
407 changes in energy metabolism intermediates in the lamellar interstitium occurred during  
408 laminitis development and were not present in plasma samples, suggesting that further  
409 investigation of local bioenergetic failure as a cause of laminitis due to sepsis is warranted.  
410 Having established the central carbon metabolome in these samples the next step would most  
411 likely be an open profiling approach to further assess the changes to the metabolome elicited  
412 by experimentally-induced laminitis.

413

#### 414 **Conflict of interest statement**

415 None of the authors of this paper has a financial or personal relationship with other  
416 people or organizations that could inappropriately influence or bias the content of the paper.

417

418 **Acknowledgements:** Supported by a Morris Animal Foundation Grant.

419

#### 420 **Appendix: Supplementary material**

421 Supplementary data associated with this article can be found in the online version at  
422 doi: [setters please insert doi number](#)

423

#### 424 **References**

- 425 Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., Walter, P., 2008. Molecular  
426 Biology of the Cell. Garland Science, United States of America.  
427  
428 Belknap, J.K., Moore, J.N., Crouser, E.C., 2009. Sepsis-From human organ failure to laminar  
429 failure. Veterinary Immunology and Immunopathology 129, 155-157.  
430  
431 Borradori, L., Sonnenberg, A., 1999. Structure and function of hemidesmosomes: more than  
432 simple adhesion complexes. Journal of Investigative Dermatology 112, 411-418.

- 433  
434 Bylesjo, M., Rantalainen, M., Cloarec, O., Nicholson, J.K., Holmes, E., Trygg, J., 2006.  
435 OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification.  
436 *Journal of Chemometrics* 20, 341-351.  
437
- 438 Callahan, L.A., Supinski, G.S., 2005. Downregulation of diaphragm electron transport chain  
439 and glycolytic enzyme gene expression in sepsis. *Journal of Applied Physiology* 99, 1120-  
440 1126.  
441
- 442 Dietmair, S., Hodson, M.P., Quek, L.E., Timmins, N.E., Gray, P., Nielsen, L.K., 2012. A  
443 Multi-Omics Analysis of Recombinant Protein Production in Hek293 Cells. *PLoS One* 7,  
444 e43394.  
445
- 446 French, K.R., Pollitt, C.C., 2004. Equine laminitis: glucose deprivation and MMP activation  
447 induce dermo-epidermal separation in vitro. *Equine Veterinary Journal* 36, 261-266.  
448
- 449 Fullerton, J.N., Singer, M., 2011. Organ failure in the ICU: cellular alterations. *Seminars in*  
450 *Respiratory and Critical Care Medicine* 32, 581-586.  
451
- 452 Goodacre, R., Vaidyanathan, S., Dunn, W.B., Harrigan, G.G., Kell, D.B., 2004.  
453 Metabolomics by numbers: acquiring and understanding global metabolite data. *Trends in*  
454 *Biotechnology* 22, 245-252.  
455
- 456 Hadrevi, J., Ghafouri, B., Sjors, A., Antti, H., Larsson, B., Crenshaw, A.G., Gerdle, B.,  
457 Hellstrom, F., 2013. Comparative metabolomics of muscle interstitium fluid in human  
458 trapezius myalgia: an in vivo microdialysis study. *European Journal of Applied Physiology*  
459 113, 2977-2989.  
460
- 461 Hodson, M.P., Dear, G.J., Griffin, J.L., Haselden, J.N., 2009. An approach for the  
462 development and selection of chromatographic methods for high-throughput metabolomic  
463 screening of urine by ultra pressure LC-ESI-ToF-MS. *Metabolomics* 5, 166-182.  
464
- 465 Kornberg, H.L., Krebs, H.A., 1957. Synthesis of cell constituents from C2-units by a  
466 modified tricarboxylic acid cycle. *Nature* 179, 988-991.  
467
- 468 Leverve, X.M., 2007. Mitochondrial function and substrate availability. *Crit Care Med* 35,  
469 S454-460.  
470
- 471 Luo, B., Groenke, K., Takors, R., Wandrey, C., Oldiges, M., 2007. Simultaneous  
472 determination of multiple intracellular metabolites in glycolysis, pentose phosphate pathway  
473 and tricarboxylic acid cycle by liquid chromatography-mass spectrometry. *Journal of*  
474 *Chromatography A* 1147, 153-164.  
475
- 476 Medina-Torres, C.E., Pollitt, C.C., Underwood, C., Castro-Olivera, E.M., Collins, S.N.,  
477 Allavena, R.E., Richardson, D.W., van Eps, A.W., 2014. Equine lamellar energy metabolism  
478 studied using tissue microdialysis. *The Veterinary Journal* 201, 275-782.  
479
- 480 Milinovich, G.J., Trott, D.J., Burrell, P.C., van Eps, A.W., Thoenner, M.B., Blackall, L.L., Al  
481 Jassim, R.A., Morton, J.M., Pollitt, C.C., 2006. Changes in equine hindgut bacterial  
482 populations during oligofructose-induced laminitis. *Environmental Microbiology* 8, 885-898.  
483

- 484 Obel, N. 1948. Studies on the Histopathology of Acute Laminitis. Thesis. Almquist and  
485 Wiksells Boktryckeri, AK, Uppsala, Sweden.  
486
- 487 Oliver, S.G., Winson, M.K., Kell, D.B., Baganz, F., 1998. Systematic functional analysis of  
488 the yeast genome. *Trends in Biotechnology* 16, 373-378.  
489
- 490 Pass, M.A., Pollitt, S., Pollitt, C.C., 1998. Decreased glucose metabolism causes separation of  
491 hoof lamellae in vitro: a trigger for laminitis? *Equine Veterinary Journal Suppl.*, 133-138.  
492
- 493 Rosdahl, H., Ungerstedt, U., Henriksson, J., 1997. Microdialysis in human skeletal muscle  
494 and adipose tissue at low flow rates is possible if dextran-70 is added to prevent loss of  
495 perfusion fluid. *Acta Physiologica Scandinavica* 159, 261-262.  
496
- 497 Sangster, T., Major, H., Plumb, R., Wilson, A.J., Wilson, I.D., 2006. A pragmatic and readily  
498 implemented quality control strategy for HPLC-MS and GC-MS-based metabonomic  
499 analysis. *Analyst* 131, 1075-1078.  
500
- 501 Singer, M., 2008. Cellular dysfunction in sepsis. *Clinical Chest Medicine* 29, 655-660, viii-ix.  
502
- 503 Steelman, S.M., Johnson, P., Jackson, A., Schulze, J., Chowdhary, B.P., 2014. Serum  
504 metabolomics identifies citrulline as a predictor of adverse outcomes in an equine model of  
505 gut-derived sepsis. *Physiological Genomics* 46, 339-347.  
506
- 507 Trygg, J., Holmes, E., Lundstedt, T., 2007. Chemometrics in metabonomics. *Journal of*  
508 *Proteome Research* 6, 469-479.  
509
- 510 van Eps, A., Collins, S.N., Pollitt, C.C., 2010. Supporting Limb Laminitis. *Veterinary Clinics*  
511 *of North America-Equine Practice* 26, 287-302.  
512
- 513 van Eps, A.W., Pollitt, C.C., 2006. Equine laminitis induced with oligofructose. *Equine*  
514 *Veterinary Journal* 38, 203-208.  
515
- 516 Want, E.J., Masson, P., Michopoulos, F., Wilson, I.D., Theodoridis, G., Plumb, R.S.,  
517 Shockcor, J., Loftus, N., Holmes, E., Nicholson, J.K., 2013. Global metabolic profiling of  
518 animal and human tissues via UPLC-MS. *Nature Protocols* 8, 17-32.  
519
- 520 Wattle, O., Pollitt, C.C., 2004. Lamellar Metabolism. *Clinical Techniques in Equine Practice*  
521 3, 22-33.  
522
- 523

524

525

Accepted Manuscript

526 **Figure Legends:**

527

528 **Figure 1:** MVA of skin and lamellar dialysate samples: (a) PCA scores plot of skin (S - blue)  
529 and lamellar (L - green) microdialysate showing similar data distributions for each tissue  
530 type. Numbers represent time points of collection; (b) PCA scores plot coloured by horse to  
531 show that some of the variance explained by the MV model is due to inter-subject (horse)  
532 variability; (c) OPLS-DA scores plot to show incomplete supervised separation between the  
533 sample metabolomes; (d) bar charts showing selected metabolites fumarate, glycolate,  
534 glyoxylate and  $\alpha$ -ketoglutarate as an example of similar distributions in skin and lamellar  
535 microdialysate.

536

537 **Figure 2:** MVA of lamellar dialysate and plasma samples: (a) PCA scores plot of lamellar  
538 dialysate (D - green) and plasma (P - blue) showing different data distributions for each  
539 tissue type. Letters next to each point represent the subject from which the sample was  
540 collected (A-D = oligofructose-treated horses; E-H = controls); (b) loadings plot for (a),  
541 highlighting the four variables (red points = metabolites; MAL: malate; PYR: pyruvate;  
542 ACO: aconitate; Glycol: glycolate shown in c-f) that were influential in the differentiation  
543 between the two tissue sample types. Profiles for (c) malate, (d) aconitate, (e) pyruvate, and  
544 (f) glycolate for each horse (X-axis: A - H) at each successive time point (0, 6, 12, 24 h =  
545 respectively, green and blue bars from left to right for each horse).

546

547 **Figure 3:** Differences in the lamellar dialysate metabolome after oligofructose treatment;  
548 OFT - red, CON - green; (a) PCA at the 6 h time point; (b) profile of malate at the 6 h time  
549 point; (c) PCA at the 12 h time point; (d) profile of pyruvate at the 12 h time point; (e) PCA  
550 at the 24 h time point; (f) profile of aconitate at the 24 h time point.

551

552 **Figure 4:** Differences in the metabolome of lamellar extracts (green) and skin extracts (blue);  
 553 (a) OPLS-DA scores plot of the extracts; (b) loadings plot of the metabolites with 4  
 554 highlighted variables (metabolites) in red, each shown in detail in c-f as column plots of (c)  
 555 citrate; (d) glycolate; (e) UDP-glucose and (f) dihydroxyacetone phosphate. The four  
 556 highlighted metabolites show a clear difference in central carbon metabolite content, which  
 557 results in separation of the two tissue extracts.

558

559 **Figure 5:** Differences in the metabolome of lamellar dialysate (green) and lamellar tissue  
 560 extracts (blue); (a) PCA scores plot of the comparison of lamellar dialysate vs. tissue extract;  
 561 (b) OPLS-DA scores plot of lamellar dialysate vs. tissue extract; c-f column plots of (c) a-  
 562 ketoglutarate; (d) aconitate; (e) dihydroxyacetone phosphate and (f) malate.

563

564 Table 1: Liquid chromatography mobile phase gradient profile.

Time (min)	Eluent A (%)
0	100
8	100
20	80
30	73
31	0
33	0
34	100
50	100

565